Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Pharma’s lung disorder therapy wins FDA nod

[Reuters] – Vertex Pharmaceuticals Inc’s unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company’s reach to the most common form of genetic . . . → Read More: Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Pharma’s lung disorder therapy wins FDA nod Similar Articles: Market Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – FDA staff say Vertex CF combo works, unclear how Stock Update (NASDAQ:VRTX): Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation